Exciva raises $59M Series B to fund Phase 2 test of Alzheimer’s agitation drug
Exciva raises $59M Series B to fund Phase 2 test of Alzheimer’s agitation drug
本文は利用できません。元の情報源をご確認ください。
Exciva raises $59M Series B to fund Phase 2 test of Alzheimer’s agitation drug